Read More

Cybin’s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What’s Next?

Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing st

CYBN

Read More

NY Supreme Court Lifts Cannabis Licensing Injunction, Process Resumes For Hundreds Of Retailers

The legal standoff that has prevented cannabis dispensaries across New York State from getting their licenses to operate was resolved late Friday when the NY Supreme Court lifted an injunction preventing the Office of Cannabis Management (OCM) from processing Conditional Adult Use Retail Dispensary —or CAURD— dispensary licenses.

ACRHF